JSPR - Jasper Therapeutics Inc logo

Jasper Therapeutics Inc

JSPR

Jasper Therapeutics develops therapies for mast cell and hematopoietic stem cell diseases. Its lead candidate, briquilimab, targets conditions like chronic urticaria and asthma, alongside conditioning agents for stem cell transplants in specific blood disorders.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$4today

Score Overview

1 Year
Scoreโ€”
Net Growth58.09%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.4
Net Growth-3.70%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyโ€”
All Time
Score
Net Growth-3.70%
Net Trend20%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Jasper Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. JSPR does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 0.51โ€”
1 Year2025-10-23
$ 2.33-78.11%
5 Years2021-10-22
$ 114.90-99.56%
All Time2021-09-24
$ 151.20-99.66%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 31M$ 7M
2025$ 0.00-$ 75M$ 28M
2024$ 0.00-$ 71M$ 71M
2023$ 0.00-$ 64M$ 86M
2022$ 13M-$ 37M$ 38M
IPO2021$ 6M-$ 30M$ 84M
JSPR - Jasper Therapeutics Inc logo

Jasper Therapeutics Inc fundamental performance

Between 2021 and 2025, revenue declined from $ 6M to $ 0.00 and net income went from -$ 30M to -$ 75M. Revenue increased in 20% of the years measured; net income in 20%.

Jasper Therapeutics Inc currently holds a 5-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.

Membership

Explore JSPR with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies